Cargando…

Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay

Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pallett, Scott J.C., Rayment, Michael, Heskin, Joseph, Mazzella, Andrea, Jones, Rachael, Mughal, Nabeela, Randell, Paul, Davies, Gary W., Moore, Luke S.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371766/
https://www.ncbi.nlm.nih.gov/pubmed/36084423
http://dx.doi.org/10.1016/j.diagmicrobio.2022.115788
_version_ 1784767230519541760
author Pallett, Scott J.C.
Rayment, Michael
Heskin, Joseph
Mazzella, Andrea
Jones, Rachael
Mughal, Nabeela
Randell, Paul
Davies, Gary W.
Moore, Luke S.P.
author_facet Pallett, Scott J.C.
Rayment, Michael
Heskin, Joseph
Mazzella, Andrea
Jones, Rachael
Mughal, Nabeela
Randell, Paul
Davies, Gary W.
Moore, Luke S.P.
author_sort Pallett, Scott J.C.
collection PubMed
description Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune status of community-based patients where laboratory-based serodiagnostics predominate. Participants were invited to undergo paired laboratory-based (Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay) and lateral flow assays (LFA; a split SARS-CoV-2 IgM/IgG and total antibody test) able to detect SARS-CoV-2 anti-spike antibodies. LFA band strength was compared with CMIA titer by log-linear regression. Two hundred individuals (median age 43.5 years, IQR 30−59; 60.5% female) underwent testing, with a further 100 control sera tested. Both LFA band strengths correlated strongly with CMIA antibody titers (P < 0.001). LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment.
format Online
Article
Text
id pubmed-9371766
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-93717662022-08-12 Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay Pallett, Scott J.C. Rayment, Michael Heskin, Joseph Mazzella, Andrea Jones, Rachael Mughal, Nabeela Randell, Paul Davies, Gary W. Moore, Luke S.P. Diagn Microbiol Infect Dis Article Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune status of community-based patients where laboratory-based serodiagnostics predominate. Participants were invited to undergo paired laboratory-based (Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay) and lateral flow assays (LFA; a split SARS-CoV-2 IgM/IgG and total antibody test) able to detect SARS-CoV-2 anti-spike antibodies. LFA band strength was compared with CMIA titer by log-linear regression. Two hundred individuals (median age 43.5 years, IQR 30−59; 60.5% female) underwent testing, with a further 100 control sera tested. Both LFA band strengths correlated strongly with CMIA antibody titers (P < 0.001). LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment. The Authors. Published by Elsevier Inc. 2022-11 2022-08-12 /pmc/articles/PMC9371766/ /pubmed/36084423 http://dx.doi.org/10.1016/j.diagmicrobio.2022.115788 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pallett, Scott J.C.
Rayment, Michael
Heskin, Joseph
Mazzella, Andrea
Jones, Rachael
Mughal, Nabeela
Randell, Paul
Davies, Gary W.
Moore, Luke S.P.
Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
title Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
title_full Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
title_fullStr Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
title_full_unstemmed Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
title_short Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
title_sort early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by sars-cov-2 anti-spike antibody specific lateral flow assay
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371766/
https://www.ncbi.nlm.nih.gov/pubmed/36084423
http://dx.doi.org/10.1016/j.diagmicrobio.2022.115788
work_keys_str_mv AT pallettscottjc earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay
AT raymentmichael earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay
AT heskinjoseph earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay
AT mazzellaandrea earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay
AT jonesrachael earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay
AT mughalnabeela earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay
AT randellpaul earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay
AT daviesgaryw earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay
AT moorelukesp earlyidentificationofhighriskindividualsformonoclonalantibodytherapyandprophylaxisisfeasiblebysarscov2antispikeantibodyspecificlateralflowassay